- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09. | Does Alpha Teknova (TKNO) Have Meaningful Growth Opportunities? | 2 | Insider Monkey | ||
| 08.08. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.07. | Alpha Teknova files $225M mixed securities shelf | 4 | Seeking Alpha | ||
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 23.06. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Alpha Teknova Q1 2025 slides: improved margins despite mixed revenue performance | 2 | Investing.com | ||
| 08.05. | Alpha Teknova GAAP EPS of -$0.09, revenue of $9.8M | 2 | Seeking Alpha | ||
| 25.04. | Alpha Teknova, Inc.: Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 | 1 | GlobeNewswire (USA) | ||
| 04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 454 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| APOGEE THERAPEUTICS | 36,860 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,210 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| BEAM THERAPEUTICS | 21,280 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 16,930 | 0,00 % | Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung | ||
| AVIDITY BIOSCIENCES | 40,190 | 0,00 % | Avidity Biosciences schließt Kapitalerhöhung über 690 Millionen US-Dollar ab | ||
| CG ONCOLOGY | 34,600 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
| RAPPORT THERAPEUTICS | 24,730 | 0,00 % | Truist Securities initiates Rapport Therapeutics stock with Buy rating | ||
| TOURMALINE BIO | 47,650 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 6,930 | 0,00 % | Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa | DJ Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa
Von Adriano Marchese
DOW JONES--Novartis hat eine potenziell milliardenschwere Entwicklungspartnerschaft mit dem US-Biotechunternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,850 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,065 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,410 | 0,00 % | Analysten-Favoriten: Raymond James setzt auf Cogent Biosciences und Dime Community |
ALPHA TEKNOVA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.